Tvardi Therapeutics (NASDAQ:TVRD) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Tvardi Therapeutics (NASDAQ:TVRD) from a hold rating to a sell rating in a research report released on Monday morning.

A number of other research firms also recently weighed in on TVRD. Raymond James Financial downgraded shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 14th. Cantor Fitzgerald lowered Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. Weiss Ratings reiterated a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 22nd. Barclays set a $5.00 target price on Tvardi Therapeutics and gave the stock an “equal weight” rating in a report on Monday, October 13th. Finally, BTIG Research dropped their price target on Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, October 13th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $55.50.

Tvardi Therapeutics Stock Performance

TVRD opened at $4.33 on Monday. The stock has a fifty day moving average of $4.26 and a 200-day moving average of $19.39. The company has a market capitalization of $40.62 million, a P/E ratio of -0.45 and a beta of 0.11. Tvardi Therapeutics has a fifty-two week low of $3.74 and a fifty-two week high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.24. Tvardi Therapeutics had a negative net margin of 585.37% and a negative return on equity of 282.16%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TVRD. Vestal Point Capital LP bought a new position in shares of Tvardi Therapeutics in the 3rd quarter valued at $6,508,000. Parkman Healthcare Partners LLC acquired a new position in Tvardi Therapeutics in the 3rd quarter worth about $2,533,000. Schonfeld Strategic Advisors LLC acquired a new position in Tvardi Therapeutics in the 3rd quarter worth about $746,000. Squarepoint Ops LLC bought a new position in Tvardi Therapeutics in the third quarter valued at about $318,000. Finally, Invesco Ltd. bought a new position in Tvardi Therapeutics in the third quarter valued at about $3,219,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.